State of the Art: Using Natriuretic Peptide Levels in Clinical PracticeAlan S. Maisel, Eugene Braunwald, Christian Mueller et al.|European Journal of Heart Failure|2008Cited by 837
Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide ConcentrationsChristian Mueller, James L. Januzzi, Kenneth McDonald et al.|European Journal of Heart Failure|2019Cited by 786
Diastolic Heart FailureRamón Martos, Kenneth McDonald, John A. Baugh et al.|Circulation|2007Cited by 461
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association ( <scp>HFA</scp> ), European Society of Cardiology ( <scp>ESC</scp> )Wouter C. Meijers, Rudolf A. de Boer, Alexandre Mebazaa et al.|European Journal of Heart Failure|2021Cited by 178
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trialJohn G.F. Cleland, Theis Lange, Mamas A. Mamas et al.|European Heart Journal|2020Cited by 143